Palatin Technologies, Inc. (PTN)
| Market Cap | 114.20M |
| Revenue (ttm) | -452,531 |
| Net Income (ttm) | -26.61M |
| Shares Out | 236.41M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $0.492 |
| Previous Close | $0.496 |
| Change ($) | -0.005 |
| Change (%) | -0.91% |
| Day's Open | 0.500 |
| Day's Range | 0.480 - 0.517 |
| Day's Volume | 1,366,399 |
| 52-Week Range | 0.375 - 1.300 |
CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity...
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -100.00% and -182.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...
CRANBURY, N.J., Feb. 17, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before ...
Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Palatin Technologies Inc (NYSE: PTN) filed an international patent application under the Patent Cooperation Treaty (PCT) related to the composition of PL9643 and a related family of melanocortin agonist...
CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.
Is (PTN) Outperforming Other Medical Stocks This Year?
CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2021 Results - Earnings Call Transcript
CRANBURY, N.J., Nov. 17, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the...
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2020 Results - Earnings Call Transcript
CRANBURY, N.J., Sept. 28, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 b...
CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc.
Shares of Palatin Technologies Inc. PTN, +2.50% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19.
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call Transcript
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript
Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call Transcript
Every 10% of market share captured by Vyleesi is likely to generate $27 million in royalties for PTN.
Palatin Technologies, Inc. (NYSEMKT:PTN) Q4 2019 Earnings Conference Call September 12, 2019 11:00 AM ET
Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.
In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.
Is (PTN) Outperforming Other Medical Stocks This Year?
Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.
A high-profile analyst questioned the company's recent FDA approval.
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc. treatment for hypoactive sex...
The demanded phase I trial showed consistent results compared to the previous trials and AMAGs CEO is: "fairly optimistic about the approval ability" of Vyleesi.
Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript
Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.
About PTN
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic ... [Read more...]
| Industry Biotechnology | IPO Date Oct 28, 1993 |
| CEO Carl Spana | Employees 20 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol PTN |
Analyst Forecasts
According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price forecast is 2.33, which is an increase of 373.67% from the latest price.